Amgen Inc. stock (US0311621009): Upcoming Jefferies appearance keeps focus on US biotech heavyweight

Amgen Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2026, while its Nasdaq-listed shares hover near recent levels amid steady institutional interest and ongoing obesity and cardiovascular pipeline development.

Amgen Inc., one of the largest biotechnology groups in the United States, has confirmed that it will present at the Jefferies Global Healthcare Conference in New York on 06/04/2026, offering investors another look at management’s strategy and pipeline priorities after its latest quarterly update, according to a company press release distributed via PR Newswire as of 05/29/2026.

The Nasdaq-listed stock trades under the ticker AMGN in the United States, and the company is headquartered in Thousand Oaks, California, anchoring it firmly in the US biotech landscape. The shares most recently changed hands at around the mid-USD 300 range on Nasdaq on 05/29/2026, with the name remaining part of the S&P 500 health care cohort, according to pricing data and index classifications from Nasdaq and S&P Dow Jones Indices as of 05/29/2026. In Germany, Amgen is also available to retail investors via off-exchange platforms such as Tradegate, where it quoted in the low EUR 300 range on 05/29/2026, based on Tradegate data as of that date.

The June Jefferies conference slot is scheduled for 9:55 a.m. ET on Thursday, 06/04/2026, and will be webcast, allowing both US and international investors to follow Amgen’s management commentary remotely, according to the same Amgen announcement as of 05/29/2026. While conference appearances do not typically move the stock on their own, they can provide incremental color on capital allocation, product launches, and regulatory milestones across oncology, inflammation, cardiovascular diseases, and obesity, which are central to Amgen’s long-term growth narrative.

At the same time, recent institutional filings show that large investors are continuing to adjust their positions in the US biotech group. Fideuram Asset Management Ireland dac opened a new stake in Amgen during the fourth quarter of 2025, acquiring 17,124 shares valued at approximately USD 5.4 million, according to a Form 13F summary cited by MarketBeat as of 05/29/2026. Another large holder, the National Pension Service of South Korea, increased its stake by 4.7% in the same quarter, highlighting ongoing interest from global pension and asset managers in the Nasdaq-listed stock, according to MarketBeat data as of 05/29/2026.

Those filings come on the heels of Amgen’s latest reported quarter, in which the company posted earnings per share of USD 5.15 compared with consensus expectations of USD 4.77 and generated revenue of USD 8.62 billion, up 5.8% year-on-year, according to analyst summary figures reported by MarketBeat as of 05/29/2026. Although those figures are compiled from analyst estimates and should be cross-checked with the company’s own filings, they show that the US biotech player continues to grow its top line and expand profitability, supporting its capacity to invest in clinical development and shareholder returns.

For retail investors in Europe who follow US health care blue-chips via German trading venues or derivative products, the upcoming Jefferies appearance can therefore serve as a reference point alongside the latest quarterly numbers and institutional position changes. While the conference is primarily a platform for global healthcare specialists, it often includes Q&A sessions where management addresses investor concerns on pricing, competition and capital deployment, areas that have shaped Amgen’s stock market performance over recent years.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Amgen
• Sector/industry: Biotechnology and biopharmaceuticals focused on specialty medicines
• Headquarters/country: Thousand Oaks, United States
• Core markets: United States, Europe, Japan and other international regions
• Key revenue drivers: Innovative therapies in oncology, inflammation, cardiovascular disease, bone health and emerging obesity treatments, supplemented by biosimilars
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen Inc.: core business model

Amgen’s operations center on discovering, developing and commercializing biologic and specialty drugs for serious diseases, with revenue primarily generated by a portfolio of blockbuster therapies in oncology, inflammation, cardiovascular conditions and newer obesity-related treatments complemented by a growing biosimilars franchise.

Insider activity and ownership structure

The most recent wave of ownership disclosures underlines that Amgen’s shareholder base remains dominated by large institutions and pension investors, with several filings in late May 2026 drawing attention to changes at the margin. According to a 05/29/2026 summary from MarketBeat as of 05/29/2026, Fideuram Asset Management Ireland dac initiated a new position in the US biotech, acquiring 17,124 shares worth about USD 5.4 million in the fourth quarter of 2025. The report notes that this holding was disclosed through the manager’s most recent Form 13F filed with the US Securities and Exchange Commission, which tracks institutional holdings above a certain threshold.

In a separate ownership update, the National Pension Service, one of South Korea’s largest public pension funds, raised its stake in Amgen by 4.7% over the same fourth-quarter period, demonstrating continued interest from long-term allocators in US-listed health care equities, according to MarketBeat as of 05/29/2026. While these moves are not insider transactions in the sense of management or board dealings, they show that institutional ownership remains an important driver of liquidity and sentiment for the Nasdaq-traded stock; detailed insider Form 4 filings with the SEC continue to provide the most direct view into executive share sales or grants, but those did not feature as a central trigger in the most recent round of disclosures.

Conclusion

Amgen’s upcoming presentation at the Jefferies Global Healthcare Conference on 06/04/2026, alongside steady institutional interest from investors such as Fideuram Asset Management Ireland dac and the National Pension Service, keeps attention on the US biotech’s strategy and execution following its latest quarterly results. For investors tracking the Nasdaq-listed stock from the United States and via German trading venues, the combination of conference commentary, recent earnings performance and ownership updates provides a structured framework to assess how Amgen is positioning its oncology, inflammation, cardiovascular and obesity portfolios in a competitive global market.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.